The aim of the study was to evaluate tolerability and clinical efficacy of two dihydropiridine calcium antagonists, felodipine and nifedipine, in patients with stable angina pectoris. Nine hundred and seventy seven patients were enrolled in 84 centers and randomized (2:1 ratio) to either felodipine ER (10 mg once-daily) or nifedipine (20 mg b.i.d.) for a 4-week period according to a randomized, parallel groups, open study design. Felodipine reduced the number of anginal episodes and nitroglycerin consumption during daily life to a greater extent than nifedipine (p <0.05); similarly, questionnaires addressed at evaluating the severity of physical activity performed by the patients during daily life also showed a more marked improvement with felodipine than with nifedipine. Exercise tolerance improved significantly with both drugs, though felodipine showed a greater antiischemic efficacy. Finally, side effects were significantly lower with once daily felodipine than with nifedipine b.i.d. both in the total population (16.5 vs 25.9%, p <0.05) and in the subgroup of patients more than 60 years old (17.5 vs 27.3%, p <0.05). In conclusion, in patients with stable angina pectoris, felodipine reduced the number of anginal episodes and improved physical activity during daily life to a greater extent than nifedipine; in addition felodipine showed a greater antiischemic effect at exercise stress testing and a lower incidence of side effects both in the whole population and in the subgroup of patients more than 60 years old.
|Translated title of the contribution||The use of a dihydropyridine calcium antagonist of the second generation (felodipine ER) in patients with stable angina pectoris|
|Number of pages||11|
|Publication status||Published - 1995|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine